Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B-Reference-Cited by-同舟云学术

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B

Published:2020-11-02 Issue:1 Volume:5 Page:34-40
ISSN:2397-9070
Container-title:JGH Open
language:en
Short-container-title:JGH Open

Author:

Itokawa Norio¹,Atsukawa Masanori¹²,Tsubota Akihito³,Takaguchi Koichi⁴,Nakamuta Makoto⁵,Hiraoka Atsushi⁶,Kato Keizo⁷,Abe Hiroshi⁷,Mikami Shigeru⁸,Shimada Noritomo⁹,Chuma Makoto¹⁰,Nozaki Akito¹⁰,Uojima Haruki¹¹,Ogawa Chikara¹²,Asano Toru¹³,Tani Joji¹⁴,Morishita Asahiro¹⁴,Senoh Tomonori⁴,Yamashita Naoki⁵,Oikawa Tsunekazu¹⁵,Matsumoto Yoshihiro¹⁶,Koeda Mai¹,Yoshida Yuji¹,Tanabe Tomohide²,Okubo Tomomi¹,Arai Taeang²,Hayama Korenobu²,Iwashita Ai‐Nakagawa²,Kondo Chisa²,Tada Toshifumi¹⁷,Toyoda Hidenori¹⁷,Kumada Takashi¹⁸,Iwakiri Katsuhiko²

Affiliation:

1. Department of Internal Medicine, Division of Gastroenterology Nippon Medical School Chiba Hokusoh Hospital Chiba Japan

2. Department of Internal Medicine, Division of Gastroenterology and Hepatology Nippon Medical School Tokyo Japan

3. Core Research Facilities The Jikei University School of Medicine Tokyo Japan

4. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

5. Department of Gastroenterology National Hospital Organization Kyushu Medical Center Fukuoka Japan

6. Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan

7. Division of Gastroenterology and Hepatology Shinmatusdo Central General Hospital Matsudo Japan

8. Department of Internal Medicine, Division of Gastroenterology Kikkoman General Hospital Noda Japan

9. Department of Internal Medicine, Division of Gastroenterology and Hepatology Otakanomori Hospital Chiba Japan

10. Gastroenterological Center Yokohama City University Medical Center Yokohama Japan

11. Department of Gastroenterology Kitasato University School of Medicine Kanagawa Japan

12. Department of Gastroenterology and Hepatology Takamatsu Red Cross Hospital Takamatsu Japan

13. Department of Internal Medicine, Division of Gastroenterology and Hepatology Tokyo Metropolitan Bokutoh Hospital Tokyo Japan

14. Department of Gastroenterology Kagawa University Graduate School of Medicine Kagawa Japan

15. Department of Gastroenterology and Hepatology The Jikei University School of Medicine Tokyo Japan

16. Department of Gastroenterology and Hepatology Jikei University School of Medicine Kashiwa Hospital Chiba Japan

17. Department of Gastroenterology Ogaki Municipal Hospital Gifu Japan

18. Department of Nursing Ogaki Women's College Gifu Japan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jgh3.12443

Reference31 articles.

1. Hepatitis B Virus Infection

2. Chronic Hepatitis B Infection

3. Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level

4. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case of Chronic Hepatitis B in which HBs Antigen Seroclearance was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up;Internal Medicine;2024

2. Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study;Medicine;2022-09-30

3. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation;Digestive Diseases and Sciences;2022-08-17

4. One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B;Medicine;2022-06-24

5. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog;PLOS ONE;2022-02-18